Job Summary

Reporting to the Chief Business and Corporate Affairs Officer, the Executive Director of IT will own and operationalize technology across the company, while helping to define the company's enterprise approach to AI. This is a doer-and-manager role: you will be responsible for the day-to-day reliability, security, and scalability of our IT platform (managing an outside IT vendor who handles much of the tactical work, including helpdesk, infrastructure support, provisioning, etc.), while also leading the technical implementation/support of our enterprise AI platform and partnering with other executives/teams to ensure AI is deployed securely and responsibly at the company.

We're looking for someone who has run IT operations at a small- to mid-size biotech/pharmaceutical company before, understands how to professionalize and scale a technology function as a company grows, and can be a strong internal partner to R&D, Clinical, Regulatory, and G&A teams. The ideal candidate also brings some familiarity with the modern AI landscape (LLM platforms, AI agents, automation tools) and is excited to help lead its responsible adoption company-wide. 

Responsibilities

IT Operations & Infrastructure

Enterprise AI Strategy & Adoption

Required Qualifications:

Preferred Qualifications:

Location and travel:

• This is a hybrid role (at least 50% of the time required in the Yardley, PA office)
• Candidate should be based in/around the greater Philadelphia area
• Occassional travel may be required

Savara provides comprehensive benefits including:

• Highly competitive medical, dental, and vision coverage
• Flexible Spending Accounts for health care and dependent care expenses
• Paid time off and paid holidays, including Dec 24-Jan 1
• Paid parental leave
• 401k with highly competitive match
• Life, AD&D, STD and LTD insurance coverage

Savara’s compensation can include an hourly rate, bonus, and equity. This position will be filled at the Associate Director or Director level. The salary range for this role is $230,000 through $275,000.

About Savara:

Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead product candidate, MOLBREEVI, is an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFLOW® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI.

Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

Our goal is to become a leader in rare respiratory disease therapeutics through the development and commercialization of novel, best-in-class medicines that address unmet medical needs in this field.

Savara is an equal opportunity employer.

MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.